USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TRIA BIOSCIENCE CORPORATION
Address:
1616 EASTLAKE AVE E
STE 260
SEATTLE, WA
Phone:
N/A
URL:
EIN:
127028759
DUNS:
831016907
Number of Employees:
7
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,888,668.00 5
SBIR Phase II $3,000,000.00 1

Award List:

Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$756,444.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and there is great concern that this virus will begin to tran smit between people and cause a global… More

A novel DC-targeting non-integrating lentivector vaccine for HIV infection

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite two decades of persistent research on prophylactic and therapeutic immunization against HIV, an effective vaccine-based solution to the HIV pandemic has remained elusive. However, the last few years have provide d important insights into the type of… More

Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Christopher H. Clegg – 206-819-9413
Abstract:
DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and there is great concern that this virus will begin to transmit between people and cause a global… More

Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Christopher H. Clegg – 206-819-9413
Abstract:
DESCRIPTION (provided by applicant): Influenza is a highly contagious respiratory disease that causes substantial mortality world-wide. There is great international concern that the Avian Influenza virus H5N1 will acquire the ability to transmit between humans and cause a global catastrophe.… More

Advanced Design of a Nicotine Vaccine for Smoking Cessation

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$352,841.00
Agency:
HHS
Principal Investigator:
Christopher H. Clegg – 206-819-9413
Abstract:
DESCRIPTION (provided by applicant): Tobacco smoke is the primary cause of lung cancer, cardiovascular disease and premature death, with nearly 5 million people dying each year. Treatments that prevent smoking will have a major impact on global health andare attractive products for commercial… More

Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$579,383.00
Agency:
HHS
Principal Investigator:
Christopher H. Clegg – 206-819-9413
Abstract:
DESCRIPTION (provided by applicant): Allergy is a major cause of illness and disability with an estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patient and its need for optimization creates a compelling business opportunity. There is a very strong… More